Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study

International Clinical Psychopharmacology

Volumn 21, Issue 4, 2006, Pages 227-231

  Mendlewicz, Julien ^a   Kriwin, Philippe ^b   Oswald, Pierre ^a   Souery, Daniel ^a   Alboni, Silvia ^c   Brunello, Nicoletta ^c  

^a ERASME HOSPITAL   (Belgium)

^b European Communication Agency   (Belgium)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Acetylsalicylic acid; Major depression; Onset of action; Selective serotonin reuptake inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; NEUROTROPISM; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; ASPIRIN; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 33646708039     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200607000-00005     Document Type: Article

References (44)

1. Abdel-Salam OM, Nofal SM, El-Shenawy SM (2003). Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol Res 48:157-165.
2. Ackerman KD, Martino M, Heyman R, Moyna NM, Rabin BS (1998). Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls. Psychosom Med 60:484-491.
3. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Press.
4. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST (2003). Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100:1751-1756.
5. Blier P (2003). The pharmacology of putative early onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66.
6. Brunello N, Alboni S, Benatti C, Capone G, Tascedda F, Blom JMC, Mendlewicz J (2006). New combinations therapies from animal to human. Eur Neuropsychopharmacol 15 (Suppl 3):S348
7. Cao Y, Prescott SM (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279-286.
8. Capuron L, Ravaud A (1999). Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 340:1370.
9. Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB (2004). Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 20:131-138.
10. Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998). Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681-686.
11. Charlton BG (2000). The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses 54:126-130.
12. Dantzer R, Bluthe RM, Gheusi G, Cremona S, Laye S, Parnet P, Kelley KW (1998). Molecular basis of sickness behavior. Ann NY Acad Sci 856:132-138.
13. De Cristobal J, Madrigal JL, Lizasoain I, Lorenzo P, Leza JC, Moro MA (2002). Aspirin inhibits stress-induced increase in plasma glutamate, brain oxidative damage and ATP fall in rats. Neuroreport 13:217-221.
14. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O (2003). Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 100:13632-13637.
15. FitzGerald GA, Patrono C (2001). The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442.
16. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, et al. (2001). Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol 58:487-492.
17. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev 17:187-205.
18. Hu F, Wang X, Pace TWW, Wu H, Miller AH (2005). Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry 10:426-433.
19. Irwin M (2002). Psychoneuroimmunology of depression: clinical implications. Brain Behav Immun 16:1-16.
20. Kenis G, Maes M (2002). Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5:401-412.
21. Kent S, Bluthe RM, Kelley KW, Dantzer R (1992). Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13:24-28.
22. Ketterer MW, Brymer J, Rhoads K, Kraft P, Lovallo WR (1996). Is aspirin, as used for antithrombosis, an emotion-modulating agent? J Psychosom Res 40:53-58.
23. Leonard BE (2001). The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 25:767-780.
24. Mendlewicz J (2001). Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection. Br J Psychiatry 42:S1-S3.
25. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K (1999). Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 156:1120.
26. Müller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029-1034.
27. Müller N, Riedel M, Schwarz MJ, Engel RR (2005). Clinical effects of COX-2 inhibitors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:149-151.
28. Nelson J (1998). Overcoming treatment resistance in depression. J Clin Psychiatry 59 (Suppl 16):13-19.
29. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-1503.
30. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49:391-404.
31. Pariante CM (2004). Glucocorticoid receptor function in vitro in patients with major depression. Stress 7:209-219.
32. Pennisi E (1998). Building a better aspirin. Science 280:1191-1192.
33. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24:778-789.
34. Price LH, Carpenter LL, Rasmussen SA (2001). Drug combination strategies. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-resistant mood disorders. Cambridge: Cambridge University Press; pp. 194-222.
35. Rapoport SI, Bosetti F (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 59:592-596.
36. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 30:805-809.
37. Staats PS (2002). Pain management and beyond: evolving concepts and treatments involving cyclooxygenase inhibition. J Pain Symptom Manag 24:S4-S9.
38. Stewart WF, Kawas C, Corrada M, Metter EJ (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-632.
39. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. (1999). Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56:407-412.
40. Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T (1996). Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Lett 215:201-204.
41. Taylor FB, Prather MR (2003). The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder. Depress Anxiety 18:83-88.
42. Thase ME, Entsuah R, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-41.
43. Vitale G, Pini LA, Ottani A, Sandrini M (1998). Effect of acetylsalicylic acid on formalin test and on serotonin system in the rat brain. Gen Pharmacol 31:753-758.
44. Xia Z, DePierre JW, Nassberger L (1996). Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34: 27-37.